Specification of endothelial cell (EC) fate during vascular development is controlled by distinct key regulators. While Notch plays an essential role in induction of arterial phenotypes, COUP-TFII is required to maintain the venous EC identity. Homeodomain transcription factor Prox1 functions to reprogram venous ECs to lymphatic endothelial cells (LECs). Here, we report that the venous EC fate regulator COUP-TFII is expressed in LECs throughout development and physically interacts with Prox1 to form a stable complex in various cell types including LECs. We found that COUP-TFII functions as a coregulator of Prox1 to control several lineage-specific genes including VEGFR-3, FGFR-3, and neuropilin-1 and is required along with Prox1 to maintain LEC phenotype. Together, we propose that the physical and functional interactions of the 2 proteins constitute an essential part in the program specifying LEC fate and may provide the molecular basis for the hypothesis of venous EC identity being the prerequisite for LEC specification.
Lymphatic endothelial cells (LECs) are derived from venous endothelial cells (ECs) during mammalian development1,2 : a subset of ECs in the cardinal vein expresses the homeodomain transcriptional factor Prox1 and migrates out to form the primitive lymphatic vessels and Prox1-deficient mice fail to form the lymphatic system. Furthermore, when ectopically expressed in postdevelopmental cultured blood vascular ECs (BECs), Prox1 can repress BEC-specific markers and up-regulate LEC-specific genes.3-10 These findings indicate that Prox1 plays as the master regulator for lymphatic system development by reprogramming cell fate of BECs to LECs. Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) is an orphan nuclear receptor and modulates transcriptional activities of its interacting partners as a coregulator to control a broad range of developmental processes.11 Although COUP-TFII is abundantly expressed in various cell types, it is only expressed in venous, but not arterial, ECs in the vascular system.12 Importantly, EC-specific genetic ablation of COUP-TFII resulted in both loss of the venous EC identity and acquisition of arterial phenotypes and, conversely, EC-specific ectopic expression of COUP-TFII disturbed normal arteriovenous specification, demonstrating that COUP-TFII functions as the key regulator to specify the venous EC identity.12 A previous LEC-lineage tracing study has proposed that the venous EC identity is a necessary prerequisite for establishment of LEC fate.13 Here we report that the venous cell fate regulator COUP-TFII physically and functionally interacts with the lymphatic master regulator Prox1 to augment and maintain LEC phenotypes.
Endothelial cell isolation for our study has been approved by the Institutional Review Board of the University of Southern California (no. HS-06-00292 to Y.H.). All microarray data have been deposited with Gene Expression Omnibus (GEO) under accession number GSE12846. For complete methods information, see Document S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article).
Results and discussion
Previously, 3 nuclear receptors (Lrh1, HNF4α, and SF-1/ff1b) have been identified to interact with Prox1 through their amino acid motif (LLLRLP) in nonendothelial cell types.14-17 To identify additional Prox1-interacting proteins that are expressed in endothelial cells, we set out to search for proteins containing the LLLRLP motif using the BLAST program (National Center for Biotechnology Information, National Institutes of Health [NIH], Bethesda, MD) and found that the same motif is present in COUP-TFII protein (Figure 1A). To investigate interaction of COUP-TFII with Prox1 protein, we performed the mammalian 2-hybrid assay using COUP-TFII and Prox1 proteins that are fused with either the GAL4 DNA-binding domain (BD) or the VP16 activation domain (AD). We found that whereas either fusion protein alone did not show any activation of the luciferase reporter in HEK293 cells, 2 fusion proteins together could yield a significant activation (Figure 1B). We next performed coimmunoprecipitation (Co-IP) studies by transfecting the expression vectors for Flag-tagged Prox1 and/or HA-tagged COUP-TFII into HEK293 cells and by precipitating protein complexes with an anti-HA antibody. Western blotting analyses with an anti-Flag antibody showed that Flag-Prox1 protein can form a stable complex with HA-COUP-TFII protein (Figure 1C). Conversely, when we pulled down protein complex with an anti-Flag antibody and analyzed by Western blotting assays with an anti-HA antibody, we found that HA-COUP-TFII protein was also precipitated with Flag-Prox1 (Figure 1D). We then performed Co-IP assays against endogenous Prox1 and COUP-TFII proteins using an anti–COUP-TFII antibody and were able to precipitate the COUP-TFII/Prox1 protein complex from whole-cell lysates of HepG2 and primary LECs in the absence or presence of ethidium bromide (EtBr), which disrupts DNA-mediated protein-protein interactions (Figure 1E,F). Together, these data demonstrate that Prox1 and COUP-TFII physically interact and form a stable complex in various cell types including primary human LECs.
We next investigated the expression pattern of COUP-TFII in LECs during lymphatic development by immunostaining. Cardinal vein–derived sprouting LECs and newly formed lymphatic vessels of mouse embryos (E11.5) showed a strong coexpression of COUP-TFII and Prox1 (Figure 1Gi-viii). LYVE-1 or Prox1-positive lymphatic vessels of human neonatal foreskins clearly expressed COUP-TFII (Figure 1Gix-xvi). Furthermore, cultured LECs expressed both Prox1 and COUP-TFII (Figure 1Gxvii-xx) and the expression levels of COUP-TFII in primary LECs and BECs isolated from neonatal human foreskins are comparable (Figure 1Gxxi-xxiv). Taken together, these data indicate that Prox1 and COUP-TFII are coexpressed in LECs throughout development.
Since COUP-TFII has been shown to coregulate the expression of target genes of its interacting proteins,11 we asked whether COUP-TFII modulates the expression of Prox1-target genes. Adenoviral expression of Prox1 and/or COUP-TFII in primary human BECs revealed that COUP-TFII and Prox1 coactivated the expression of FGFR-3, a Prox1 target gene that is more prominently expressed in LECs compared with BECs6 (Figure 2A). Furthermore, luciferase assays using a 3-kb FGFR-3 promoter construct demonstrated that the proximal promoter can mediate their cooperative transcriptional activation (Figure 2B). Notably, a DNA-binding defective mutant of Prox16,8 failed to show the activation, suggesting that DNA binding of Prox1 is necessary for their coregulation of FGFR-3 (Figure 2B). We then performed siRNA-mediated knockdown of Prox1 and/or COUP-TFII in cultured LECs to investigate the necessity of COUP-TFII to maintain the expression of LEC-associated genes.3-10 Knockdown of Prox1 and COUP-TFII resulted in a concerted down-regulation of FGFR-3 and VEGFR-3 (Figure 2C-E). In comparison, some LEC-associated genes are regulated by either protein alone: while LYVE-1 was predominantly regulated by COUP-TFII, podoplanin and ABCA4 were mainly regulated by Prox1 (Figure 2F,H,K). Furthermore, ICAM1, MCP-1, and versican, which are more abundantly expressed in BECs than in LECs,5,7,8,10 were cooperatively up-regulated by knockdown of Prox1 and COUP-TFII (Figure 2I,J,K), suggesting that their expression in LECs are suppressed by both Prox1 and COUP-TFII. Interestingly, the expression of neuropilin-1 was counter-regulated by the 2 proteins in LECs (Figure 2G). We then investigated alteration of genome-wide gene expression profile by knockdown of Prox1 and/or COUP-TFII in primary LECs using microarrays and found that COUP-TFII variously modulates the expression of many Prox1 target genes, which further corroborates their functional relationship as coregulators. The microarray data are summarized in the supplemental data (Figure S1, Tables S1Table S2. Genes that are upregulated by knockdown of Prox1 and/or COUP-TFII for 48 hours in cultured LECs (PDF, 114 KB)–S3). Taken together, we conclude that COUP-TFII functions as an important coregulator of Prox1 and plays an essential role in establishing LEC fate.
Previous studies1,2,12 have shown that the nuclear receptor COUP-TFII is a key regulator of the venous EC identity and that LECs are differentiated from venous ECs through the function of Prox1. Moreover, a lineage-tracing study has proposed that the venous EC identity is a necessary prerequisite for LEC specification.13 Here, we demonstrate that COUP-TFII physically interacts with Prox1 and is required to modulate Prox1-mediated lineage-specific gene expression in LECs. Our findings strongly agree with the previous hypothesis13 of the venous identity being a prerequisite for LEC specification. Furthermore, we propose that the physical and functional interaction of Prox1 and COUP-TFII may be an important constitute in the program specifying for LEC fate during vascular development. Since COUP-TFII is the first Prox1-interacting partner identified to date that has been reported to play an essential role in EC fate determination, it will be of great interest to better understand the molecular mechanism underlying Prox1 and COUP-TFII–mediated transcriptional regulation during the lymphatic reprogramming of venous EC during development.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
The authors thank Drs You-Hua Xie (Shanghai Institute for Biological Sciences, Shanghai, People's Republic of China) and Eckardt Treuter (Karolinska Institutet, Stockholm, Sweden) for Flag-Prox1 vectors.
This study was supported by the CIRM fellowship (San Francisco, CA), a predoctoral NIH Training Grant (National Institutes of Health, Bethesda, MD), the Margaret Early Foundation Award (Los Angeles, CA), American Heart Society (Burlingame, CA), Concern Foundation (Beverly Hills, CA), American Cancer Society (Atlanta, GA), March of Dimes Foundation (White Plains, NY), and NIH/NHLBI (National Heart, Lung, and Blood Institute; 1R21HL082643-01).
National Institutes of Health
Contribution: S.L., J.K., J.Y., S.K.G., S.C.C., S.R., B.A., and J.L. performed experiments and analyzed data; and S.L. and Y.-K.H. designed research, analyzed data, and wrote the manuscript.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Young-Kwon Hong, PhD, 1450 Biggy Street NRT6501, Mail Code 9601, Los Angeles, CA 90033; e-mail: email@example.com.